TITLE

Evaluating dose response from flexible dose clinical trials

AUTHOR(S)
Lipkovich, Ilya; Adams, David H.; Mallinckrodt, Craig; Faries, Doug; Baron, David; Houston, John P
PUB. DATE
January 2008
SOURCE
BMC Psychiatry;2008, Vol. 8, Special section p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related. Methods: To evaluate dose effect in response on primary efficacy scales from 2 randomized, double-blind, flexible-dose trials of patients with bipolar mania who received olanzapine (N = 234, 5-20 mg/day), or patients with schizophrenia who received olanzapine (N = 172, 10-20 mg/day), we used marginal structural models, inverse probability of treatment weighting (MSM, IPTW) methodology. Dose profiles for mean changes from baseline were evaluated using weighted MSM with a repeated measures model. To adjust for selection bias due to non-random dose assignment and dropouts, patient-specific time-dependent weights were determined as products of (i) stable weights based on inverse probability of receiving the sequence of dose assignments that was actually received by a patient up to given time multiplied by (ii) stable weights based on inverse probability of patient remaining on treatment by that time. Results were compared with those by unweighted analyses. Results: While the observed difference in efficacy scores for dose groups for the unweighted analysis strongly favored lower doses, the weighted analyses showed no strong dose effects and, in some cases, reversed the apparent "negative dose effect." Conclusion: While naïve comparison of groups by last or modal dose in a flexible-dose trial may result in severely biased efficacy analyses, the MSM with IPTW estimators approach may be a valuable method of removing these biases and evaluating potential dose effect, which may prove useful for planning confirmatory trials.
ACCESSION #
35702784

 

Related Articles

  • The effects of chronic lithium treatment on psychomotor performance related to driving. Hatcher, Simon; Sims, Ruth; Thompson, David; Hatcher, S; Sims, R; Thompson, D // British Journal of Psychiatry;Aug90, Vol. 157, p275 

    A group of 16 psychiatric out-patients in remission, who had been taking lithium carbonate as their sole medication for at least three months, were compared with a control group of 22 healthy volunteers. On a computerised driving simulator which produced measures of reaction time, tracking...

  • Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Chue, Pierre; Jones, Barry; Taylor, Cindy C; Dickson, Ruth // Canadian Journal of Psychiatry;Oct2002, Vol. 47 Issue 8, p771 

    Objective: This pilot study investigates the dissolution profile, tolerability, and acceptability of an orally disintegrating olanzapine tablet in patients with schizophrenia. Method: Eleven patients with schizophrenia stabilized on oral olanzapine (mean dosage 12.7 mg...

  • Lithium dosage and inositol levels. Grisaru, Nimrod; Belmaker, R.H.; Grisaru, N // British Journal of Psychiatry;Jan94, Vol. 164, p133 

    A letter to the editor is presented about the ability of lithium to reduce brain inositol levels by inhibition of inositol monophosphatase.

  • Lamotrigine use in geriatric patients with bipolar depression. Robillard, Matthew; Conn, David K // Canadian Journal of Psychiatry;Oct2002, Vol. 47 Issue 8, p767 

    Objective: To study the effectiveness of adding lamotrigine to the treatment of inpatient geriatric patients with bipolar disorder (BD) who were in the depressed phase and had been on lithium and valproate for at least 3 months.Method: Lamotrigine was started at 25 mg...

  • FORGET GINKGO FOR DEMENTIA. Gregory, Ann // Medical Journal of Australia;1/5/2009, Vol. 190 Issue 1, p44 

    The article discusses a randomized controlled trial which compared the effectiveness of a twice-daily dose of 120 milligrams of Ginkgo biloba with placebo in 3,069 community volunteers with either normal cognition or mild cognitive impairment. It references a study published in the 2008 issue of...

  • A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Sharman, Jeffrey P.; Wheler, Jennifer J.; Einhorn, Lawrence; Dowlati, Afshin; Shapiro, Geoffrey I.; Hilton, John; Burke, John M.; Siddiqi, Tanya; Whiting, Nancy; Jalal, Shadia I. // Investigational New Drugs;Aug2019, Vol. 37 Issue 4, p738 

    Summary: Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-label study evaluated the...

  • Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Gao, Keming; Mackle, Mary; Cazorla, Pilar; Zhao, Jun; Szegedi, Armin // Neuropsychiatric Disease & Treatment;2013, Vol. 9, p1145 

    Background: Patients with schizophrenia or bipolar disorder (BPD) may be differentially sensitive to antipsychotics. This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications. Methods: Ten clinical trials...

  • Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Francobandiera, Giorgio; Francobandiera, G // Canadian Journal of Psychiatry;May2001, Vol. 46 Issue 4, p356 

    Objective: This study evaluates the clinical response to olanzapine used in association with selective serotonin reuptake inhibitors (SSRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD). Methods: We describe the cases of 9 patients with...

  • Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response. Marder, Stephen R.; Midha, Kamal K.; Van Putten, Theodore; Aravagiri, Manickam; Hawes, Edward M.; Hubbard, John W.; McKay, Gordon; Mintz, Jim; Marder, S R; Midha, K K; Van Putten, T; Aravagiri, M; Hawes, E M; Hubbard, J W; McKay, G; Mintz, J // British Journal of Psychiatry;May91, Vol. 158, p658 

    The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three months to reach a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics